Pan Aurora Kinase Inhibitor: A Promising Targeted-Therapy in Dedifferentiated Liposarcomas With Differential Efficiency Depending on Sarcoma Molecular Profile

Cancers
Jean Camille MatteiCarine Jiguet-Jiglaire

Abstract

Soft tissue sarcoma (STS) are rare and aggressive tumours. Their classification includes numerous histological subtypes of frequent poor prognosis. Liposarcomas (LPS) are the most frequent type among them, and the aggressiveness and deep localization of dedifferentiated LPS are linked to high levels of recurrence. Current treatments available today lead to five-year overall survival has remained stuck around 60%-70% for the past three decades. Here, we highlight a correlation between Aurora kinasa A (AURKA) and AURKB mRNA overexpression and a low metastasis - free survival. AURKA and AURKB expression analysis at genomic and protein level on a 9-STS cell lines panel highlighted STS heterogeneity, especially in LPS subtype. AURKA and AURKB inhibition by RNAi and drug targeting with AMG 900, a pan Aurora Kinase inhibitor, in four LPS cell lines reduces cell survival and clonogenic proliferation, inducing apoptosis and polyploidy. When combined with doxorubicin, the standard treatment in STS, aurora kinases inhibitor can be considered as an enhancer of standard treatment or as an independent drug. Kinome analysis suggested its effect was linked to the inhibition of the MAP-kinase pathway, with differential drug resistance profiles ...Continue Reading

References

Nov 13, 2001·Developmental Cell·E FormstecherH Chneiweiss
Feb 1, 2002·The Journal of Biological Chemistry·Damu TangAlistair J Ingram
Aug 15, 2002·The Journal of Cell Biology·Thomas A KuferErich A Nigg
Sep 6, 2002·Biochemical Pharmacology·Jacques PouysségurPhilippe Lenormand
Jun 17, 2003·Molecular and Cellular Biology·Alessandra TrenciaFrancesco Beguinot
Dec 4, 2003·Current Opinion in Cell Biology·Paul D AndrewsJason R Swedlow
Feb 5, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·I Ray-CoquardJ-Y Blay
Dec 2, 2004·Nature Reviews. Cancer·Nicholas Keen, Stephen Taylor
Feb 11, 2005·Laboratory Investigation; a Journal of Technical Methods and Pathology·Ahmed IdbaihAlain Aurias
Feb 22, 2005·Current Medicinal Chemistry. Anti-cancer Agents·Jun Zhou, Paraskevi Giannakakou
May 4, 2005·Trends in Cell Biology·Régis GietClaude Prigent
Jul 6, 2006·Bioinformatics·Philippe La RosaEmmanuel Barillot
Nov 7, 2006·IUBMB Life·Zhimin Lu, Shuichan Xu
Jul 6, 2007·PloS One·Simone LemeerJeroen den Hertog
Aug 19, 2007·Molecular & Cellular Proteomics : MCP·Simone LemeerMonique Slijper
Feb 22, 2008·Current Cancer Drug Targets·P Sapra SharmaR Tyagi
Apr 2, 2008·Current Oncology Reports·Steven L WarnerDaniel D Von Hoff
Nov 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Patrick G Morris, Monica N Fornier
Oct 22, 2009·The FEBS Journal·Sebastien Cagnol, Jean-Claude Chambard
Mar 5, 2011·Microbiology and Molecular Biology Reviews : MMBR·Marie Cargnello, Philippe P Roux
Mar 1, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jason J LukeGary K Schwartz
Jan 1, 2014·Pathology·Vickie Y Jo, Christopher D M Fletcher
Feb 10, 2016·Frontiers in Oncology·Andrew BurgessElgene Lim
Feb 18, 2016·Oncotarget·Jayasree S Nair, Gary K Schwartz
Apr 30, 2016·Acta Biochimica Et Biophysica Sinica·Xiaoxia WangBinquan Wang
Jun 2, 2016·Acta histochemica·Miroslava JuríkováIvan Varga
Aug 10, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A DicksonG K Schwartz
Oct 6, 2016·Cancer Medicine·Zhu XingyuSong Yangrong

❮ Previous
Next ❯

Citations

Sep 17, 2020·Cancers·Antonio Ruggiero
May 28, 2020·BMC Research Notes·Kazuhiko HashimotoMasao Akagi
Jan 28, 2021·International Journal of Molecular Sciences·Emi MashimaMotonobu Nakamura

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies
transfection
PCR

Software Mentioned

ImageJ
Evolve
CellQuest Pro

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis